Colorectal cancer screening: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(33 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
{{tocleft}}
{{Colon cancer}}
{{Colon cancer}}
To view the screening of familial adenomatous polyposis (FAP), click [[Familial adenomatous polyposis differential screening|'''here''']]<br>
To view the screening of familial adenomatous polyposis (FAP), click [[Familial adenomatous polyposis differential screening|'''here''']]<br>
To view the screening of hereditary nonpolyposis colorectal cancer (HNPCC), click [[Hereditary nonpolyposis colorectal cancer differential screening|'''here''']]<br><br>
To view the screening of hereditary nonpolyposis colorectal cancer (HNPCC), click [[Hereditary nonpolyposis colorectal cancer differential screening|'''here''']]<br><br>
{{CMG}} {{AE}} Elliot B. Tapper, M.D.; Saarah T. Alkhairy, M.D.
{{CMG}} {{AE}}; {{RAK}} Elliot B. Tapper, M.D.; Saarah T. Alkhairy, M.D.


==Overview==
==Overview==
Current guidelines recommend that colonoscopy is the optimal screening tool for colon cancer since it detects 98-99% of the cases.<ref name="colorectal">American Society of Clinical Oncology. 2010. Progress in Cancer Screening. http://owl.english.purdue.edu/owl/resource/560/10/</ref> High risk individuals include a first-degree relative with colorectal cancer. A [[colonoscopy]] every 10 years reduces the risk of left-sided colon cancer. Right sided colon cancers are more likely to be missed because they are harder to reach and they could be flat, which means they would be harder to detect.  Flat growths (non-polypoid) are difficult to detect and are more likely to progress to colon cancer compared to cylindrical [[polyps]].<ref name="colorectal">American Society of Clinical Oncology. 2010. Progress in Cancer Screening. http://owl.english.purdue.edu/owl/resource/560/10/</ref>
Early detection of premalignant colorectal masses or early-stage colorectal cancers is essential in treating these patients and possibly preventing cancer or colorectal cancer related death. According to the [[United states preventive services task force recommendations scheme|USPSTF]] (United States Preventive Services Task Force): [[Screening]] for colorectal cancer is recommended among adults older than 50 years of age and do not have an increased risk of developing the disease (average-risk adults).  


==Colorectal Cancer Screening==
==Clinical practice guidelines==


Colorectal cancer may take several years to develop. If colorectal cancer is detected early, the chances of a cure is greatly improved. The patient population can be divided into average, moderate, and high risk.  
According to the '''USPSTF''' (United States Preventive Services Task Force):<ref name="pmid27304597">{{cite journal| author=US Preventive Services Task Force. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW et al.| title=Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. | journal=JAMA | year= 2016 | volume= 315 | issue= 23 | pages= 2564-2575 | pmid=27304597 | doi=10.1001/jama.2016.5989 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27304597  }}</ref>
* Screening for colorectal cancer is recommended among adults older than 50 years of age and do not have an increased risk of developing the disease ('''average-risk''' adults).
* Decision to screen for colorectal cancer among adults aged 76 to 85 years is an individual one.
** Screening would be more beneficial for healthier individuals that are able to undergo possible treatment.
* Screening for colorectal cancer among adults aged 86 years and older is not recommended.
* No preference is given to one screening modality over the other
** Decision should be shared and according to the patient's preferences when it comes to choosing an option.
* Screening options:<ref name="pmid27304597" />
*# '''[[Colonoscopy]]'''
*# '''FIT'''
*#* Fecal immunochemical testing for occult blood
*# '''[[Flexible sigmoidoscopy]]'''
*# '''Flexible sigmoidoscopy''' + '''FIT'''
*# '''CT colonography'''
*# '''FIT-DNA'''
*#* multitargeted stool DNA testing
*# '''gFOBT'''
*#* Guaiac-based fecal occult blood testing


The alogorithm below demonstrates a screening protocol for '''average risk''' patients.  
Screening for colorectal cancer in individuals that are at increased risk of developing the disease is different and depends on several factors:<ref name="Lieberman2009">{{cite journal|last1=Lieberman|first1=David A.|title=Screening for Colorectal Cancer|journal=New England Journal of Medicine|volume=361|issue=12|year=2009|pages=1179–1187|issn=0028-4793|doi=10.1056/NEJMcp0902176}}</ref><ref name="pmid27304597" />
<gallery widths=800px>
* Family history of colorectal cancer before age 50
** Begin screening at an earlier age
* Risk of rapid disease progression
** Perform screening more frequently
* Family history of [[Hereditary nonpolyposis colorectal cancer|HNPCC]] or [[FAP]]
** Use most sensitive screening modality: colonoscopy


Average risk CRC.jpg | Colorectal Cancer Screening Recommendation for Individuals at Average Risk <br> [https://www.rmf.harvard.edu/~/media/Files/_Global/KC/PDFs/RMFCRC.pdf/ <font size="-2">''Adapted from CRICO/RMF Colorectal Cancer Screening Algorithm''</font>]
== Screening protocols summarized in the figures below: ==
Protocols have been summarized according to USPSTF guidelines.<ref name="pmid27304597" />[[Image:Average risk CRC.jpg|center|500x500px|frame|Screening protocol for '''average risk''' patients]]


</gallery>


The alogorithm below demonstrates a screening protocol for '''moderate risk''' patients.
[[Image:Moderate risk CRC.jpg|center|500x500px|frame|Screening protocol for '''moderate risk''' patients]]
<gallery widths=200px>


Moderate risk CRC.jpg | Colorectal Cancer Screening Recommendation for Individuals at Average Risk <br> [https://www.rmf.harvard.edu/~/media/Files/_Global/KC/PDFs/RMFCRC.pdf/ <font size="-2">''Adapted from CRICO/RMF Colorectal Cancer Screening Algorithm''</font>]
[[Image:High risk CRC.jpg|center|500x500px|frame|Screening protocol for '''high risk''' patients]]


</gallery>
==Types of Screening Methods==


The alogorithm below demonstrates a screening protocol for '''high risk''' patients.  
===Fecal Occult Blood Testing===
<gallery widths=200px>
*A [[fecal occult blood]] test is a test for blood in the stool.
* There are two types of tests that can be used for detecting occult blood in stools:<ref name="pmid27304597" /><ref name="pmid20824704">{{cite journal| author=Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R et al.| title=Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. | journal=Int J Cancer | year= 2011 | volume= 128 | issue= 1 | pages= 3-11 | pmid=20824704 | doi=10.1002/ijc.25654 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20824704  }}</ref>
*# '''FIT'''
*#* Fecal immunochemical testing for occult blood
*# '''gFOBT'''
*#* Guaiac-based fecal occult blood testing
* Use of low-sensitivity guaiac fecal tests is not recommended due to its of low sensitivity.<ref name="pmid27304597" />


High risk CRC.jpg | Colorectal Cancer Screening Recommendation for Individuals at Average Risk <br> [https://www.rmf.harvard.edu/~/media/Files/_Global/KC/PDFs/RMFCRC.pdf/ <font size="-2">''Adapted from CRICO/RMF Colorectal Cancer Screening Algorithm''</font>]
===Endoscopy===
 
*A [[sigmoidoscopy|'''sigmoidoscopy''']] is a lighted probe ([[sigmoidoscope]]) that is inserted into the [[rectum]] and lower [[colon]] to check for [[polyps]] and other abnormalities.<ref name="pmid16635231" />
</gallery>
*A [[colonoscopy|'''colonoscopy''']] is a lighted probe ([[colonoscope]]) that is inserted into the [[rectum]] and the entire [[colon]] to look for [[polyp (medicine)|polyp]]s and other abnormalities that may be caused by [[cancer]]. A [[colonoscopy]] has the advantage that if [[polyp (medicine)|polyp]]s are found during the procedure they can be immediately removed, and the tissue can also be taken for [[biopsy]]. The [http://www.asge.org/ American Society for Gastrointestinal Endoscopy] has released quality indicators for screening [[colonoscopy]], which include:<ref name="pmid16635231">{{cite journal| author=Rex DK, Petrini JL, Baron TH, Chak A, Cohen J, Deal SE et al.| title=Quality indicators for colonoscopy. | journal=Am J Gastroenterol | year= 2006 | volume= 101 | issue= 4 | pages= 873-85 | pmid=16635231 | doi=10.1111/j.1572-0241.2006.00673.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16635231  }} </ref>
The most common indicator of high risk is a first-degree relative with colorectal cancer a personal history of inflammatory bowel disease<ref name="Lieberman2009">{{cite journal|last1=Lieberman|first1=David A.|title=Screening for Colorectal Cancer|journal=New England Journal of Medicine|volume=361|issue=12|year=2009|pages=1179–1187|issn=0028-4793|doi=10.1056/NEJMcp0902176}}</ref>.
:*Documentation of prep quality
*If the first-degree relative was diagnosed with CRC before 50 years of age
:*Photo documentation of [[Cecum|cecal]] [[intubation]]
:*The individual should be suspected of a hereditary syndrome
:*Withdrawal time of 6 minutes or more
:*A complete family history, genetic counseling and testing, and an appropriate timing for endoscopic surveillance should be obtained
:*[[Adenoma]] detection rate of greater than 25% in males and 15% in females greater than 50 years old
*If a first-degree relative was diagnosed with CRC at 50 years of age or older the lifetime risk of CRC nearly doubles among his or her family members


===Clinical practice guidelines===
[[Image:Colorectal cancer endo 2.jpg|473x473px]]
'''[[Clinical practice guideline]]s by the United States Preventive Service Task Force ([[USPSTF]]) in 2008 stated:'''<ref name="pmid18838716">{{cite journal| author=U.S. Preventive Services Task Force| title=Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. | journal=Ann Intern Med | year= 2008 | volume= 149 | issue= 9 | pages= 627-37 | pmid=18838716 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18838716  }} </ref>
*"The USPSTF recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75 years"
*"The USPSTF recommends against routine screening for colorectal cancer in adults 76 to 85 years of age. There may be considerations that support colorectal cancer screening in an individual patient"
*"The USPSTF recommends against screening for colorectal cancer in adults older than age 85 years"


The USPSTF concludes that the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing as screening modalities for colorectal cancer.  
=== CT colonography ===
:* Also known as Virtual Colonoscopy
:* Requires special workstation software in order for the [[radiologist]] to interpret 
:* This technique is approaching [[colonoscopy]] in sensitivity for [[polyps]]
:* Any polyps found must still be removed by standard [[colonoscopy]]<ref name="pmid14657435">{{cite journal| author=Morrin MM, LaMont JT| title=Screening virtual colonoscopy--ready for prime time? | journal=N Engl J Med | year= 2003 | volume= 349 | issue= 23 | pages= 2261-4 | pmid=14657435 | doi=10.1056/NEJMe038181 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14657435  }}</ref>


'''The American College of Gastroenterology recommends:'''<ref>Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009.Am J Gastroenterol. 2009 Mar;104(3):739-50.</ref>  
=== Fecal DNA testing ===
* Screening in African Americans should begin at age 45 years
:* Multitargeted stool DNA testing
* CT colonography every 5 years is the radiographic screening alternative, when patients decline colonoscopy
:* Ability to detect mutations from DNA shed by colorectal cancer<ref name="pmid15017656">{{cite journal| author=Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D| title=Fecal multiple molecular tests to detect colorectal cancer in stool. | journal=Clin Gastroenterol Hepatol | year= 2003 | volume= 1 | issue= 5 | pages= 377-83 | pmid=15017656 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15017656  }}</ref>
* Fecal immunochemical test for blood (FIT) is preferred over guaiac-based fecal occult blood testing


===Types of Screening Methods===
==Accuracy of screening methods==


====Fecal Occult Blood Testing====
Advanced adenomas are defined as being ≥10 mm, having villous histology, or having high grade dysplasia. Advanced neoplasia is defined as cancer or advanced adenoma<ref name="pmid27441328">{{cite journal| author=Lin JS, Piper MA, Perdue LA, Rutter C, Webber EM, O’Connor E | display-authors=etal| title=Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force | journal=U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews | year= 2016 | volume= | issue= | pages=  | pmid=27441328 | doi= | pmc= | url= }} </ref>.
*A [[fecal occult blood]] test (FOBT) is a test for blood in the stool
* There are two types of tests that can be used for detecting occult blood in stools: guaiac-based (chemical test) and immunochemical


====Endoscopy====
{| class="wikitable"
*A [[sigmoidoscopy]] is a lighted probe (sigmoidoscope) that is inserted into the rectum and lower colon to check for polyps and other abnormalities
|+ Accuracy of screening tests to detect colorectal cancer and advanced adenomas<ref name="pmid34003220">{{cite journal| author=Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR| title=Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. | journal=JAMA | year= 2021 | volume= 325 | issue= 19 | pages= 1978-1997 | pmid=34003220 | doi=10.1001/jama.2021.4417 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34003220 }} </ref>.
*A [[colonoscopy]] is a lighted probe (colonoscope) that is inserted into the rectum and the entire colon to look for [[polyp (medicine)|polyp]]s and other abnormalities that may be caused by cancer. A colonoscopy has the advantage that if [[polyp (medicine)|polyp]]s are found during the procedure they can be immediately removed, and the tissue can also be taken for [[biopsy]]. The [http://www.asge.org/ American Society for Gastrointestinal Endoscopy] has released quality indicators for screening colonoscopy, which include:<ref name="pmid16635231">{{cite journal| author=Rex DK, Petrini JL, Baron TH, Chak A, Cohen J, Deal SE et al.| title=Quality indicators for colonoscopy. | journal=Am J Gastroenterol | year= 2006 | volume= 101 | issue= 4 | pages= 873-85 | pmid=16635231 | doi=10.1111/j.1572-0241.2006.00673.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16635231 }} </ref>
|-
:*Documentation of prep quality
! Method
:*Photo documentation of cecal intubation
! Sensitivity
:*Withdrawal time of 6 minutes or more
! Specificity
:*Adenoma detection rate of greater than 25% in males and 15% in females greater than 50 years old.
|-
| colspan="3" style="text-align:center;" | Colorectal cancer
|-
| Colonoscopy
| NA
| NA
|-
| Fecal Immunochemical Test (FIT)
| 74
| 94
|-
| Cologuard (sDNA + FIT)
| 93
| 85
|-
| colspan="3" style="text-align:center;" | Advanced adenoma
|-
| Colonoscopy (for adenoma > 10 mm)
| 89 to 95
| NA
|-
| Fecal Immunochemical Test (FIT)
| 23
| 96
|-
| Cologuard (sDNA + FIT)
| 43
| 89
|}


[[Image:Colorectal cancer endo 2.jpg|200px]]
== References ==
 
====Genetic Testing====
*[[Genetic counseling]] and [[genetic testing]] is a screening modality for families who may have a hereditary form of colon cancer, such as [[hereditary nonpolyposis colorectal cancer]] (HNPCC) or [[familial adenomatous polyposis]] (FAP)
 
====Other Screening Techniques====
*Double contrast barium enema (DCBE)
:*First, an overnight preparation is taken to cleanse the colon.  An [[enema]] containing [[barium sulfate]] is administered, then air is insufflated into the colon, distending it.  The result is a thin layer of barium over the inner lining of the colon which is visible on X-ray films.  A cancer or a precancerous polyp can be detected this way.  This technique can miss the (less common) flat polyp.
*[[Virtual colonoscopy]]
:* This is also known as CT colonography
:* This replaces X-ray films in the double contrast barium enema (above) with a special [[computed tomography]] scan and requires special workstation software in order for the [[radiologist]] to interpret.  This technique is approaching [[colonoscopy]] in sensitivity for polyps. However, any polyps found must still be removed by standard colonoscopy.
*[[Blood tests]]
:*The measurement of the patient's blood for elevated levels of certain [[proteins]] can give an indication of tumor load.  In particular, high levels of [[carcinoembryonic antigen]] (CEA) in the blood can indicate [[metastasis]] of [[adenocarcinoma]].  These tests are frequently [[Type I and type II errors|false positive]] or [[Type I and type II errors|false negative]], and are not recommended for screening, it can be useful to assess disease recurrence.
* Stool DNA testing
:* This detects DNA that sheds into the stool from the cells of pre-malignant adenomas and cancers. The DNA is not degraded during the digestive process and remains in the stool.
 
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Disease]]
[[Category:Disease]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Oncology]]
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Conditions diagnosed by stool test]]
[[Category:Conditions diagnosed by stool test]]
Line 93: Line 127:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Gastroenterology]]
[[Category:Surgery]]

Latest revision as of 15:03, 2 June 2021

Colorectal cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Colorectal cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Metastasis Treatment

Primary Prevention

Secondary Prevention

Follow-up

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Colorectal cancer screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Colorectal cancer screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Colorectal cancer screening

CDC on Colorectal cancer screening

Colorectal cancer screening in the news

Blogs on Colorectal cancer screening

Directions to Hospitals Treating Colorectal cancer

Risk calculators and risk factors for Colorectal cancer screening

To view the screening of familial adenomatous polyposis (FAP), click here
To view the screening of hereditary nonpolyposis colorectal cancer (HNPCC), click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: ; Roukoz A. Karam, M.D.[2] Elliot B. Tapper, M.D.; Saarah T. Alkhairy, M.D.

Overview

Early detection of premalignant colorectal masses or early-stage colorectal cancers is essential in treating these patients and possibly preventing cancer or colorectal cancer related death. According to the USPSTF (United States Preventive Services Task Force): Screening for colorectal cancer is recommended among adults older than 50 years of age and do not have an increased risk of developing the disease (average-risk adults).

Clinical practice guidelines

According to the USPSTF (United States Preventive Services Task Force):[1]

  • Screening for colorectal cancer is recommended among adults older than 50 years of age and do not have an increased risk of developing the disease (average-risk adults).
  • Decision to screen for colorectal cancer among adults aged 76 to 85 years is an individual one.
    • Screening would be more beneficial for healthier individuals that are able to undergo possible treatment.
  • Screening for colorectal cancer among adults aged 86 years and older is not recommended.
  • No preference is given to one screening modality over the other
    • Decision should be shared and according to the patient's preferences when it comes to choosing an option.
  • Screening options:[1]
    1. Colonoscopy
    2. FIT
      • Fecal immunochemical testing for occult blood
    3. Flexible sigmoidoscopy
    4. Flexible sigmoidoscopy + FIT
    5. CT colonography
    6. FIT-DNA
      • multitargeted stool DNA testing
    7. gFOBT
      • Guaiac-based fecal occult blood testing

Screening for colorectal cancer in individuals that are at increased risk of developing the disease is different and depends on several factors:[2][1]

  • Family history of colorectal cancer before age 50
    • Begin screening at an earlier age
  • Risk of rapid disease progression
    • Perform screening more frequently
  • Family history of HNPCC or FAP
    • Use most sensitive screening modality: colonoscopy

Screening protocols summarized in the figures below:

Protocols have been summarized according to USPSTF guidelines.[1]

Screening protocol for average risk patients


Screening protocol for moderate risk patients
Screening protocol for high risk patients

Types of Screening Methods

Fecal Occult Blood Testing

  • A fecal occult blood test is a test for blood in the stool.
  • There are two types of tests that can be used for detecting occult blood in stools:[1][3]
    1. FIT
      • Fecal immunochemical testing for occult blood
    2. gFOBT
      • Guaiac-based fecal occult blood testing
  • Use of low-sensitivity guaiac fecal tests is not recommended due to its of low sensitivity.[1]

Endoscopy

  • Documentation of prep quality
  • Photo documentation of cecal intubation
  • Withdrawal time of 6 minutes or more
  • Adenoma detection rate of greater than 25% in males and 15% in females greater than 50 years old

CT colonography

  • Also known as Virtual Colonoscopy
  • Requires special workstation software in order for the radiologist to interpret
  • This technique is approaching colonoscopy in sensitivity for polyps
  • Any polyps found must still be removed by standard colonoscopy[5]

Fecal DNA testing

  • Multitargeted stool DNA testing
  • Ability to detect mutations from DNA shed by colorectal cancer[6]

Accuracy of screening methods

Advanced adenomas are defined as being ≥10 mm, having villous histology, or having high grade dysplasia. Advanced neoplasia is defined as cancer or advanced adenoma[7].

Accuracy of screening tests to detect colorectal cancer and advanced adenomas[8].
Method Sensitivity Specificity
Colorectal cancer
Colonoscopy NA NA
Fecal Immunochemical Test (FIT) 74 94
Cologuard (sDNA + FIT) 93 85
Advanced adenoma
Colonoscopy (for adenoma > 10 mm) 89 to 95 NA
Fecal Immunochemical Test (FIT) 23 96
Cologuard (sDNA + FIT) 43 89

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 US Preventive Services Task Force. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW; et al. (2016). "Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement". JAMA. 315 (23): 2564–2575. doi:10.1001/jama.2016.5989. PMID 27304597.
  2. ↑ Lieberman, David A. (2009). "Screening for Colorectal Cancer". New England Journal of Medicine. 361 (12): 1179–1187. doi:10.1056/NEJMcp0902176. ISSN 0028-4793.
  3. ↑ Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R; et al. (2011). "Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper". Int J Cancer. 128 (1): 3–11. doi:10.1002/ijc.25654. PMID 20824704.
  4. ↑ 4.0 4.1 Rex DK, Petrini JL, Baron TH, Chak A, Cohen J, Deal SE; et al. (2006). "Quality indicators for colonoscopy". Am J Gastroenterol. 101 (4): 873–85. doi:10.1111/j.1572-0241.2006.00673.x. PMID 16635231.
  5. ↑ Morrin MM, LaMont JT (2003). "Screening virtual colonoscopy--ready for prime time?". N Engl J Med. 349 (23): 2261–4. doi:10.1056/NEJMe038181. PMID 14657435.
  6. ↑ Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D (2003). "Fecal multiple molecular tests to detect colorectal cancer in stool". Clin Gastroenterol Hepatol. 1 (5): 377–83. PMID 15017656.
  7. ↑ Lin JS, Piper MA, Perdue LA, Rutter C, Webber EM, O’Connor E; et al. (2016). "Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force". U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. PMID 27441328.
  8. ↑ Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR (2021). "Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 325 (19): 1978–1997. doi:10.1001/jama.2021.4417. PMID 34003220 Check |pmid= value (help).


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Colorectal_cancer_screening&oldid=1702836"